Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Autor: Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)

Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment

Externí odkaz: https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f

Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

Autor: Özgecan Dülgar, Başak Bala Öven, Muhammed Mustafa Atcı, Rukiye Arıkan, Seval Ay, Murat Ayhan, Oğuzhan Selvi, Deniz Tataroglu Ozyukseler, Ertuğrul Bayram, Erkan Özcan, Ayşe İrem Yasin, Mahmut Gümüş

Publikováno v: Expert Review of Anticancer Therapy. 22:773-780

Background Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0571c521d2d9822c93b445b5fe9351bd
https://doi.org/10.1080/14737140.2022.2076670

Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?

Autor: Filiz Özülker, Çağlayan Geredeli, Sevda Sağlampınar Karyağar, Serdar Arici, Oğuzhan Selvi, Savaş Karyağar, Osman Güven

Publikováno v: Nuclear medicine communications. 42(9)

Objective In patients with metastatic castration-resistant prostate cancer (mCRPCa), enzalutamide is administered when docetaxel treatment fails. The purpose of the study was to evaluate the relationship between prostate-specific antigen (PSA) respon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756814d8482a6f5d970e032ea08b4dbb
https://pubmed.ncbi.nlm.nih.gov/33958536